Video recording
OtherPatients' performance of MDS-UPDRS III will be recorded.
NCT Number: NCT05906719
The Movement Disorders Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III (MDS-UPDRS III) is the primary assessment method for motor symptoms in Parkinson's disease patients. Currently, movement disorder specialists conduct semi-quantitative scoring, which entails limitations such as subjectivity, weak sensitivity, and a limited number of professional physicians. This study, based on machine vision, establishes gold standard labels according to expert scoring. By using machine learning, we develop a machine rating model and compare the model's performance with gold standard rating and general clinical rating to investigate the accuracy of machine vision-based MDS-UPDRS III machine rating.
Looking for future studies?
Notify Me20 year–80 year
All sexes
Observational
Beijing Hospital, Neurology Department, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients' performance of MDS-UPDRS III will be recorded.
Time frame: 1 day
At the item level, mean absolute error (MAE) between paired AI scores and consensus reference scores, calculated as the average absolute difference across items. Lower values indicate closer agreement.
Time frame: 1 day
At the item level, the proportion of paired AI and consensus reference scores with an absolute difference of 2 or more points. Lower values indicate fewer large item-level scoring disagreements.
Time frame: 1 day
Intraclass correlation coefficient (ICC) between AI-derived scores and consensus reference scores, calculated separately for each of the four subdomain scores and the total score. Higher ICC values indicate greater agreement.
Time frame: 1 day
Standard error of measurement (SEM) for AI-derived scores relative to consensus reference scores, calculated separately for each of the four subdomain scores and the total score. SEM quantifies measurement error in the units of the corresponding score, with lower values indicating greater measurement precision.
Time frame: 1 day
Smallest detectable change (SDC), derived from the measurement error and calculated separately for each of the four subdomain scores and the total score. SDC represents the minimum score change required to exceed expected measurement error. Lower values indicate greater measurement precision.
Time frame: 1 day
At the item level, ACC1 is defined as the proportion of paired AI and consensus reference scores with an absolute difference of no more than 1 point, i.e., P(|Δ| ≤ 1). Higher values indicate closer item-level agreement.
Time frame: 1 day
At the item level, exact-error proportions, P(|Δ| = k), represent the proportions of paired AI and consensus reference scores with each exact absolute error magnitude k. In particular, P(|Δ| = 0) corresponds to exact-match accuracy (ACC), defined as the proportion of items for which the AI score exactly matches the consensus reference score. The remaining values of k characterize the distribution of item-level scoring errors.
Time frame: 1 day
At the item level, for each consensus reference score class, the proportion of items for which the AI score exactly matches the consensus reference score among all items belonging to that reference class. Higher values indicate better class-specific exact agreement.
Time frame: 1 day
At the item level, a cross-tabulation of AI scores against consensus reference scores, showing the number of paired ratings for each combination of reference and AI score categories. Rows represent consensus reference scores and columns represent AI scores.
Time frame: 1 day
At the item level, the confusion matrix normalised within each consensus reference score row so that each row sums to 1, showing the distribution of AI scores conditional on each reference score class.
Time frame: 1 day
Bland-Altman limits of agreement between AI-derived scores and consensus reference scores, calculated separately for each of the four subdomain scores and the total score. The limits characterize the range within which most paired differences between AI and reference scores are expected to fall.
Time frame: 1 day
Mean absolute error (MAE) between AI-derived scores and consensus reference scores, calculated separately for each of the four subdomain scores and the total score as the average absolute difference between paired scores. Lower values indicate smaller scoring errors.
Time frame: 1 day
Root mean square error (RMSE) between AI-derived scores and consensus reference scores, calculated separately for each of the four subdomain scores and the total score. RMSE gives greater weight to larger scoring errors, with lower values indicating closer agreement.
Time frame: 1 day
Spearman rank correlation between AI-derived scores and consensus reference scores, calculated separately for each of the four subdomain scores and the total score. Higher values indicate a stronger monotonic association between AI-derived and reference scores.
Ruijin Hospital
Other
Machine Vision Based Machine Rating of MDS-UPDRS III
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05356845
Basal Ganglia Diseases, Brain Diseases
Copenhagen, Denmark
View Trial DetailsNCT05608915
Basal Ganglia Diseases, Brain Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT04925622
Autonomic Nervous System Diseases, Basal Ganglia Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT03065192
Basal Ganglia Disease, Basal Ganglia Diseases
San Francisco, California, United States
View Trial Details